Medical device comprising boswellic acid

Patent metadata

Field	Value
Publication number	US-12083146-B2
Application number	US-202117402172-A
Country	US
Kind code	B2
Filing date	Aug 13, 2021
Priority date	Jun 21, 2011
Publication date	Sep 10, 2024
Grant date	Sep 10, 2024

Abstract

A medical composition and devices made from the composition for the delivery of extracts obtained from Boswellia genus, similar compounds synthetically derived, and in particular derivatives of triterpenes is disclosed. The medical device may be implantable, or alternatively a device which contacts the interior of a mammalian body. The medical device may be comprised, of or present an absorbable component containing Boswellia derivatives, or an eluting component. When administered into a particular body site, the Boswellia component may be released substantially and immediately, released slowly, or not released, into the body and residing actively on the medical device surface.

First claim

What is claimed is:

1. A method for enhancing the therapeutic activity of a pentacyclic acidic fraction from Boswellia genus, said method comprising: attachment of a polyol to a hydroxyl group residing on a boswellic acid fraction derived from Boswellia extract via an isocyanate group to provide a product having enhanced biological activity, wherein an amount of Boswellia extract is used so that a percent nitrogen-carbon-oxygen (% NCO) content is equal to zero.

2. The method according to claim 1 , wherein said polyol is comprised of one or more of polyethylene oxide and polypropylene oxide.

3. The method according to claim 1 , wherein said polyol is attached to said boswellic acid fraction via one or more urethane links.

4. The method according to claim 1 , wherein said product contains multiple boswellic acid fractions per molecule.

5. The method according to claim 1 , wherein said polyol is an ethylene oxide.

6. The method according to claim 1 , wherein said polyol is a propylene oxide.

7. The method according to claim 1 , wherein said polyol is a copolymer of ethylene oxide and propylene oxide blocks.

8. The method according to claim 1 , wherein said polyol contains greater than 2 hydroxyl groups.

9. The method according to claim 1 , wherein the product comprises acetyl-11-keto-beta-boswellic acid (AKBA) in an amount greater than about 20% of the total boswellic acids by weight.

10. The method according to claim 1 , wherein the method further comprises using a solubilizing agent and a physiologically compatible carrier.

11. The method according to claim 10 , wherein said solubilizing agent is propylene carbonate.

12. The method according to claim 10 , wherein said physiologically compatible carrier is propylene carbonate.

13. The method according to claim 10 , wherein said solubilizing and carrier agents do not contain available hydroxyl groups.

Assignees

• Bvw Holding Ag

Inventors

• Milbocker Michael
• Bluecher Lukas

Classifications

• C08G18/771

  oxygen · CPC title

• C08G18/348

  Hydroxycarboxylic acids · CPC title

• A61L31/16

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title

• A61K31/19

  Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title

• A61L31/041

  Mixtures of macromolecular compounds · CPC title